Drug trial aims to halt deadly lung scarring
NCT ID NCT03385668
Summary
This small study tested whether a drug called pirfenidone could safely slow the progression of lung scarring (pulmonary fibrosis) in patients who also have a specific immune system marker or related blood vessel inflammation. The trial involved 7 adults with this specific condition over 52 weeks. Researchers measured changes in lung function and walking ability to see if the drug could help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin Hospital
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.